Address: Lechner Odon Fasor 6 Millennium Torony I H-1095 Budapest,Hungary
Tel: +36 1 299 8910
Web: http://www.boehringer-ingelheim.com/
he Boehringer Ingelheim group of companies´ objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept ‘Lead & Learn’, this vision is the driver of our corporate culture.
A new vision for a new world
Our corporate vision – ‘Value through Innovation’: The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped us to build on our strengths and make the most of our distinctive character. In a competitive and fast-changing world, the value of products, services and companies is constantly changing. Real customer value today can only be created by constantly developing new solutions and doing what we already do better.
Lead & Learn: The present phase in our evolution is Lead & Learn. Since 2004, it outlines ways in which Boehringer Ingelheim realises and delivers Value through Innovation. As our corporate culture, Lead & Learn is about all the people at Boehringer Ingelheim and how they work together.
A new vision for the corporate culture: Lead & Learn superseded the concept of Vision & Leadership that was established in 1993 by the Shareholders and the Board of Managing Directors of the Boehringer Ingelheim corporation. The Vision, created for Boehringer Ingelheim worldwide, was built around the corporate vision of Value through Innovation. Since then, our corporate culture always was guided by this vision.
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Our businesses comprise Human Pharmaceuticals and Animal Health. The Human Pharmaceuticals business area covers the segments Prescription Medicines, Consumer Health Care, Biopharmaceuticals and Operations (Chemical Production and Pharma Production).
Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in…
Dr Ildikó Horvath, Hungary’s State Secretary for Health explains her role and shares insights on the key health trends in Hungary, the government’s top priority in improving healthcare, the importance…
Here we highlight five of the most important women working in healthcare and the life sciences in Central & Eastern Europe (CEE) today. From regulators to pharma affiliate heads with…
As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist…
Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s…
Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and…
Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient…
Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG…
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology…
See our Cookie Privacy Policy Here
